DrugPatentWatch Database Preview
NUVESSA Drug Profile
Which patents cover Nuvessa, and when can generic versions of Nuvessa launch?
Nuvessa is a drug marketed by Chemo Research Sl and is included in one NDA. There are six patents protecting this drug.
This drug has fifteen patent family members in nine countries.
The generic ingredient in NUVESSA is metronidazole. There are eighteen drug master file entries for this compound. Seventy-seven suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
Summary for NUVESSA
| International Patents: | 15 |
| US Patents: | 6 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 125 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | NUVESSA at DailyMed |
Pharmacology for NUVESSA
| Drug Class | Nitroimidazole Antimicrobial |
US Patents and Regulatory Information for NUVESSA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | See Pricing | ||||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| Chemo Research Sl | NUVESSA | metronidazole | GEL;VAGINAL | 205223-001 | Mar 24, 2014 | RX | Yes | Yes | See Pricing | See Pricing | Y | See Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NUVESSA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2725904 | See Pricing |
| Argentina | 070406 | See Pricing |
| Japan | 6235087 | See Pricing |
| Japan | 2017014248 | See Pricing |
| World Intellectual Property Organization (WIPO) | 2013003646 | See Pricing |
| China | 103763925 | See Pricing |
| Japan | 2014518272 | See Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NUVESSA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0328535 | 96C0021 | Belgium | See Pricing | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
